Proanthocyanidins as a Potential Novel Way for the Treatment of Hemangioma
Ran Tang, Dehai Xian, Jixiang Xu, Huiling Peng, Shihong Pan, Jianqiao Zhong
Abstract
Hemangioma, the most common benign vascular tumor, not only affects the appearance and psychology but also has a life‐threatening potential. It is considered that clonal vascular endothelial cell proliferation and excessive angiogenesis are responsible for hemangioma pathogenesis, in which abnormal cytokines/pathways are closely implicated, primarily including high expression of hypoxia‐inducible factor‐1 α (HIF‐1 α ) and vascular endothelial growth factor (VEGF) as well as their downstream pathways, especially phosphatidylinositol 3‐kinase (PI3K)/protein kinase B (Akt). These further stimulate the migration and proliferation of vascular endothelial cells and promote the formation of new vessels, ultimately leading to the occurrence and development of hemangioma. Proanthocyanidins are naturally active substance from plants and fruits. They possess multiple functions like antiproliferation, antiangiogenesis, and antitumor. It has been demonstrated that proanthocyanidins effectively work in various diseases via inhibiting the expression of various factors, e.g., HIF‐1 α , VEGF, PI3K, and Akt. Considering the pathogenesis of hemangioma and the effect of proanthocyanidins, we hold a hypothesis that proanthocyanidins would be applied in hemangioma via downregulating cytokine/pathway expression, suppressing vascular cell proliferation and arrest abnormal angiogenesis. Taken together, proanthocyanidins may be a potential novel way for the treatment of hemangioma.